Sunitinib Prolongs Survival in Genetically Engineered Mouse Models of Multistep Lung Carcinogenesis
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Non–small cell lung cancer (NSCLC) has a poor prognosis, with substantial mortality rates even among patients diagnosed with early-stage disease. There are few effective measures to block the development or progression of NSCLC. Antiangiogenic drugs represent a new class of agents targeting multiple aspects of tumor progression, including cell proliferation, invasion, migration, and outgrowth of metastatic deposits. We tested the multitargeted angiogenesis inhibitor sunitinib in a novel endogenous mouse model of NSCLC, which expresses a conditional activating mutation in Kras with or without conditional deletion of Lkb1; both alterations are frequent in human NSCLC. We showed that daily treatment with sunitinib reduced tumor size, caused tumor necrosis, blocked tumor progression, and prolonged median survival in both the metastatic (Lkb1/Kras) and nonmetastatic (Kras) mouse models; median survival was not reached in the nonmetastatic model after 1 year. However, the incidence of local and distant metastases was similar in sunitinib-treated and untreated Lkb1/Kras mice, suggesting that prolonged survival with sunitinib in these mice was due to direct effects on primary tumor growth rather than to inhibition of metastatic progression. These collective results suggest that the use of angiogenesis inhibitors in early-stage disease for prevention of tumor development and growth may have major survival benefits in the setting of NSCLC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
Pignon, J.-P., Tribodet, H., Scagliotti, G. V., Douillard, J.-Y., Shepherd, F. A., Stephens, R. J., Dunant, A., Torri, V., Rosell, R., Seymour, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9030 · Cited by 2,642 · cited 13×
“Therefore, identifying targets for early interventions designed to prevent tumor development and suppress early tumor progression could favorably affect the survival rates of NSCLC patients.”
BackgroundInfluentialGlobal Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer
Rikova, K., Guo, A., Zeng, Q., Possemato, A., Yu, J., Haack, H., Nardone, J., Lee, K., Reeves, C., Li, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.11.025 · Cited by 2,317
Self-citationLKB1 modulates lung cancer differentiation and metastasis
Ji, H., Ramsey, M. R., Hayes, D. N., Fan, C., McNamara, K., Kozlowski, P., Torrice, C., Wu, M. C., Shimamura, T., Perera, S. A., et al. (2007) · Nature · doi:10.1038/nature06030 · Cited by 1,064 · cited 6×
“These mice develop tumors generally within 4 weeks of activation of conditional mutations and die within 8 to 10 weeks, with local and distant metastases (18).”
BackgroundMethodSelf-citationZhu, C.-Q., da Cunha Santos, G., Ding, K., Sakurada, A., Cutz, J.-C., Liu, N., Zhang, T., Marrano, P., Whitehead, M., Squire, J. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8924 · Cited by 661
NSCLC Meta-Analyses Collaborative Group (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.7162 · Cited by 604
Ji, H., Li, D., Chen, L., Shimamura, T., Kobayashi, S., McNamara, K., Mahmood, U., Mitchell, A., Sun, Y., Al-Hashem, R., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.04.022 · Cited by 462
Self-citationThe hypoxic response of tumors is dependent on their microenvironment
Blouw, B., Song, H., Tihan, T., Bosze, J., Ferrara, N., Gerber, H.-P., Johnson, R. S., & Bergers, G. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00194-6 · Cited by 408 · cited 1×
“Alternatively, some studies have actually suggested that blockade of angiogenesis leads to increased invasive behavior of tumors (31, 32).”
BackgroundLe Calvez, F., Mukeria, A., Hunt, J. D., Kelm, O., Hung, R. J., Tanière, P., Brennan, P., Boffetta, P., Zaridze, D. G., & Hainaut, P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0551 · Cited by 273 · cited 1×
“Kras mutations are present in 15% to 30% of NSCLC patients and some studies have suggested an association with a history of smoking (18, 34, 35).”
Background
Cited by
Antiangiogenic therapy: impact on invasion, disease progression, and metastasis
Ebos, J. M. L., & Kerbel, R. S. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.21 · Cited by 685
“—an example is a model of NSCLC where sunitinib prolonged survival but longer treatments (initiated earlier) did not translate into greater benefit”
BackgroundSvensson, R. U., Parker, S. J., Eichner, L. J., Kolar, M. J., Wallace, M., Brun, S. N., Lombardo, P. S., Van Nostrand, J. L., Hutchins, A., Vera, L., et al. (2016) · Nature Medicine · doi:10.1038/nm.4181 · Cited by 536
“We also performed analogous CRISPR/Cas9 studies in a mouse Kras G12D/+, p53 −/− NSCLC cell line (634T) 22 and found that Acc1 deletion led to a proliferation defect and that Acc2 deletion had no impact (Supplementary Fig.1f, g, h).”
Pathways mediating VEGF-independent tumor angiogenesis
Ferrara, N. (2010) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.11.003 · Cited by 313
Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not?
De Bock, K., Mazzone, M., & Carmeliet, P. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.83 · Cited by 293
Ebos, J. M. L., Lee, C. R., & Kerbel, R. S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0095 · Cited by 291
Metadata
- Authors
- Gandhi, L., McNamara, K. L., Li, D., Borgman, C. L., McDermott, U., Brandstetter, K. A., Padera, R. F., Chirieac, L. R., Settleman, J. E., & Wong, K.-K.
- Venue
- Cancer Prevention Research
- Published
- 2009-04-01
- Volume
- 2
- Issue
- 4
- Pages
- 330-337
- ISSN
- 1940-6207 (ISSN-L)
- 1940-6215
- OpenAlex
- W2152131956
- Cited by
- 39
- References
- 8
- FWCI
- 2.76
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sunitinib Prolongs Survival in Genetically Engineered Mouse Models of Multistep Lung Carcinogenesis. https://app.cochat.ai/papers/10.1158/1940-6207.capr-08-0213
- The paper
- Gandhi, L., McNamara, K. L., Li, D., Borgman, C. L., McDermott, U., Brandstetter, K. A., Padera, R. F., Chirieac, L. R., Settleman, J. E., & Wong, K.-K. (2009). Sunitinib Prolongs Survival in Genetically Engineered Mouse Models of Multistep Lung Carcinogenesis. Cancer Prevention Research. https://doi.org/10.1158/1940-6207.capr-08-0213
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.